University of Maryland Baltimore, School of Medicine, Baltimore, MD 21201-1595, USA.
Am J Kidney Dis. 2012 Apr;59(4):541-9. doi: 10.1053/j.ajkd.2011.11.038. Epub 2012 Feb 17.
Lok et al previously reported a risk equation for arteriovenous fistula (AVF) maturation failure. It is unclear whether this model or a more comprehensive model correlates with incident AVF use in the US hemodialysis population.
Cross-sectional study.
SETTING & PARTICIPANTS: 195,756 adult patients initiating outpatient hemodialysis therapy in the United States between July 1, 2005, and December 31, 2009, with 6 months or more prior nephrology care.
Patient characteristics (age, peripheral vascular disease, coronary artery disease, and race) populating the AVF maturation failure risk equation and other demographic and clinical variables from the Centers for Medicare & Medicaid Services (CMS) Medical Evidence Report (CMS 2728).
OUTCOMES & MEASUREMENTS: AVF use at first outpatient dialysis treatment as recorded on the CMS 2728.
Using the risk categories defined by Lok et al, AVF use varied from 19.0% (very high risk) to 25.6% (low risk). In a model using only these risk categories, logistic regression showed lower ORs for moderate-, 0.90 (95% CI, 0.88-0.93); high-, 0.80 (95% CI, 0.78-0.83); and very high-risk patients, 0.68 (95% CI, 0.63-0.73) compared with low risk. In the expanded model, odds were lower for women, blacks, Hispanics, age older than 85 years, diabetes, peripheral vascular disease, congestive heart failure, other cardiac disease, and underweight. Odds were higher for hypertension, overweight, obesity, 12 months or more nephrologist care, most insurance types, and each successive year after 2005. Despite associations, the C statistic for the expanded model was 0.64.
This analysis is limited by lack of access creation history before dialysis therapy initiation and minimal external validation of CMS 2728 data.
Clinical risk factors identified by Lok and expanded in this analysis have limited ability to predict incident AVF use. Even patients judged at highest risk can have successful AVF construction and initiate dialysis therapy through a functioning AVF.
Lok 等人之前报告了动静脉瘘(AVF)成熟失败的风险方程。目前尚不清楚该模型或更全面的模型与美国血液透析人群中动静脉瘘的使用是否相关。
横断面研究。
2005 年 7 月 1 日至 2009 年 12 月 31 日期间在美国接受门诊血液透析治疗的 195756 名成年患者,这些患者在开始接受肾脏科治疗前有 6 个月或更长时间的治疗。
患者特征(年龄、外周血管疾病、冠状动脉疾病和种族),这些特征构成了 AVF 成熟失败风险方程,并纳入了来自医疗保险和医疗补助服务中心(CMS)医疗证据报告(CMS 2728)的其他人口统计学和临床变量。
根据 Lok 等人定义的风险类别,AVF 的使用率从 19.0%(极高风险)到 25.6%(低风险)不等。在仅使用这些风险类别的模型中,逻辑回归显示,中度风险患者的 OR 值降低,为 0.90(95%置信区间,0.88-0.93);高风险患者的 OR 值降低,为 0.80(95%置信区间,0.78-0.83);极高风险患者的 OR 值降低,为 0.68(95%置信区间,0.63-0.73),与低风险患者相比。在扩展模型中,女性、黑人、西班牙裔、年龄大于 85 岁、糖尿病、外周血管疾病、充血性心力衰竭、其他心脏疾病和体重不足的患者的几率较低。高血压、超重、肥胖、接受 12 个月或更长时间的肾脏科治疗、大多数保险类型以及 2005 年后的每一年,患者的几率都会增加。尽管存在关联,但扩展模型的 C 统计量为 0.64。
该分析受到缺乏透析治疗开始前通路创建历史记录的限制,以及对 CMS 2728 数据进行最小限度的外部验证。
Lok 等人确定的临床危险因素对预测动静脉瘘的使用能力有限。即使是被认为风险最高的患者也可以成功建立动静脉瘘,并通过功能正常的动静脉瘘开始透析治疗。